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Abstract
Previous studies indicate that FDG PET/CT may predict pathological response in patients
undergoing neoadjuvant chemo-radiotherapy for locally advanced rectal cancer (LARC).
Aim of the current study is evaluate if pathological response can be similarly predicted in
LARC patients after short course radiation therapy alone. Methods: Thirty-three patients
with cT2-3, N0-2, M0 rectal adenocarcinoma treated with hypo fractionated short course
neoadjuvant RT (5x5 Gy) with delayed surgery (SCRTDS) were prospectively studied. All
patients underwent 3 PET/CT studies at baseline, 10 days from RT end (early), and 53 days
from RT end (delayed). Maximal standardized uptake value (SUVmax), mean standardized
uptake value (SUVmean) and total lesion glycolysis (TLG) of the primary tumor were mea-
sured and recorded at each PET/CT study. We use logistic regression analysis to aggregate
different measures of metabolic response to predict the pathological response in the course
of SCRTDS. Results: We provide straightforward formulas to classify response and esti-
mate the probability of being a major responder (TRG1-2) or a complete responder (TRG1)
for each individual. The formulas are based on the level of TLG at the early PET and on the
overall proportional reduction of TLG between baseline and delayed PET studies. Conclu-
sions: This study demonstrates that in the course of SCRTDS it is possible to estimate the
probabilities of pathological tumor responses on the basis of PET/CT with FDG. Our
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formulas make it possible to assess the risks associated to LARC borne by a patient in the
course of SCRTDS. These risk assessments can be balanced against other health risks
associated with further treatments and can therefore be used to make informed therapy
adjustments during SCRTDS.
Introduction
In patients with LARC, SCRTDS is known to be a valuable therapeutic option. As compared to
traditional neoadjuvant radiochemotherapy (NRC), SCRTDS leads to similar results in terms
of the rate of R0 resection and satisfactory results in terms of downstaging and pathological
response [1–3]. When compared to short course radiation therapy (SCRT), SCRTDS is known
to lead to downsizing of the lesions ensuring a significant rate of pathological response [4–6]
and can be considered in patients with locally advanced tumors unfit for chemo-radiation [7–
9]. Unfortunately, not all patients benefit equally from neoadjuvant treatments and using new
imaging modalities to make individual assessments of response to therapy could be of great
clinical value to adjust subsequent strategies for each individual patient. Such strategies range
from a tailored surgical approach, to administering an adjuvant regimen, or even to a wait and
see policy without surgery for patients with high surgical risks [10, 11]. Conventional imaging
modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and
endorectal ultrasound (EUS), successfully used for the initial staging of rectal cancer, perform
poorly after neoadjuvant therapies, given that they are unable to accurately distinguish desmo-
plastic reactions or fibrosis from still viable tumors [12–14].
PET/CT with [18F]-FDG has been shown to predict response during NRC in LARC as well
as in advanced esophageal cancer patients [15–19]. Nevertheless, few studies have addressed
the evaluation of response with PET/CT with [18F]-FDG after SCRT [20–22] and to our
knowledge no studies have evaluated the role of PET/CT results/parameters in predicting
pathological response in the course of SCRTDS.
The aim of the current study is to investigate whether multiple semi quantitative parameters
obtained from sequential PET/CT studies can be employed to assess the effects of preoperative
radiation therapy using histopathology response as a gold standard for pathological response.
Materials and Methods
Patient characteristics
Thirty-three consecutive patients with histologically proven LARC, who refused or were con-
sidered unfit for chemo radiation and planned for treatment with neoadjuvant SCRTDS, were
prospectively evaluated in this study. Patient characteristics are described in Table 1. Patients
had T2-T3 rectal cancer with or without local lymph node involvement. Patients staged T2
without lymph node involvement were included only if the tumor was located at less than 5
cm from the anal verge.
Staging included EUS and/or MRI of the pelvis (with endorectal contrast media); contrast
enhanced MRI of the liver, CT of the abdomen and pelvis and whole body PET/CT with [18F]-
FDG. According to Gunderson’s risk of recurrence stratification [23], 15 patients were at inter-
mediate risk, 13 at moderately high risk, 4 at high risk and only 1 at low risk.
Patients were included in the study in accordance with the approved guidelines of our ethi-
cal committee and gave their written informed consent.
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Preoperative radiotherapy
All patients underwent dose-planning CT in the prone position. CT images from the baseline
PET/CT studies were used for treatment planning. The planning target volume (PTV) was
generated according to ICRU recommendations [24, 25]. Three-dimensional plans were gen-
erated for a dual-energy (6 and 20MV x-rays) linear accelerator (Clinac 2100, Varian Medical
Systems, Palo Alto, CA) equipped with multileaf collimators (MLC). Patients were planned
using a 3 field arrangement to include the PTV within the 95% isodose and a dose of 25 Gy in
5 fractions over 1 week was prescribed to the ICRU 62 intersection point.
PET/CT with [18F]-FDG
FDG PET/CT studies were acquired with a Discovery 600 hybrid scanner (GE Healthcare, Mil-
waukee, WI, USA) under standard fasting conditions with measured blood glucose levels
below 150 mg/dl. No oral or intravenous contrast media were administered for the CT study.
Each patient underwent 3 PET/CT studies: baseline, on average 10.7 days before starting
radiotherapy; early, on average 10.1 days after the end of radiotherapy and delayed, on average
53 days after the end of RT and 7.3 days before surgery (Fig 1). The PET scan timings were
chosen on the basis of previous published data on patients that underwent radiochemotherapy
[15–17]. Volumes of interest (VOI) were drawn to define the extent of LARC and the relative
analysis was performed using Volume Viewer software on a dedicated workstation (GE
Advantage Workstation 4.4) by two experienced nuclear medicine physicians (Fig 2). The VOI
was defined with a threshold method in which all pixels above a SUV value of 3 were included.
The following parameters were recorded: SUVmax, defined as the maximum SUV value
within the target volume; SUVmean, the average SUV value of all pixels included in the target
volume; Metabolic Tumor Volume (MTV), the volume of all pixels in the target volume; Total
Lesion Glycolysis (TLG), defined as the product of SUVmean and MTV.
Table 1. Patient descriptive characteristics.
Characteristics Statistics
Sex No. of male 26
No. of female 7
Age Mean ± SD 68.8 ± 10.7
Median 70
cTNM (clinical TNM) T3N2 9%
T3N1 46%
T3N0 39%
T2N1 3%
T2N0 3%
cCRM (mm) (clinical Cinconferential Resection Margin) n.d. 37%
> 5 39%
< 5 24%
GR (Gunderson Risk classification) High 12%
Moderately high 39%
Intermediate 46%
Low 3%
Tumor Location (cm from anal verge) > 5 70%
= 5 6%
< 5 24%
doi:10.1371/journal.pone.0169462.t001
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Surgery
Surgery was performed on average 60.3 days after the end of radiotherapy. Based on the results
of restaging and downsizing, sphincter-saving surgery was considered for all patients without
a clear sphincter involvement before treatment and local excision was considered for patients
with a significant clinical response. The planned operation was discussed with the patients and
a specific informed consent was obtained. A rectal resection with total meso-rectal excision
and bilateral nerve sparing, when possible, was the standard approach. In distal cancers an
ultra-low anterior resection with colo-anal manual anastomosis or, in case of sphincter
involvement, an abdomino-perineal resection were performed. All patients receiving an anas-
tomosis underwent construction of a protecting ileostomy.
Pathology
Postsurgical pathology examination provided a macroscopic description of the mesorectum
and of the former tumor-bearing area; at least four paraffin blocks were processed and an addi-
tional larger area block was embedded. If no tumor was visible, the entire suspicious area was
sliced and embedded.
Tumor regression grade (TRG) was scored based on a five-point system, as previously
reported, after being independently evaluated by two pathologists [26]. Lesions were scored
Fig 1. Schematic diagram of the Timing of PET/CT evaluation relative to treatment procedures.
doi:10.1371/journal.pone.0169462.g001
Fig 2. Sequential PET/CT studies in patient n. 2. Transaxial fused PET/CT images obtained in the prone position in the basal (a), early (b)
and delayed (c) studies. A clear progressive reduction in FDG accumulation of the rectal lesion can be appreciated. This patient had a
complete pathological response on pathological analysis (TRG1).
doi:10.1371/journal.pone.0169462.g002
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from TRG 1 (complete pathologic response) to TRG 5 (clear signs of tumor progression). In
case of discrepancy between the two pathologists, the worse TRG score was assigned. Patients
were classified as pathological major responders (TRG1-2), complete responders (TRG1) or
non-responders (TRG3-5) based on these findings.
Statistics
The principal objective of this work is to predict the pathological response to SCRT on the
basis of PET/CT parameters. We consider logistic regression models to estimate the probabil-
ity of a major response (TRG1-2) or of a complete response (TRG1).
As compared to performing discrimination analysis, such as ROC analysis, this approach
has two advantages:
• It makes it possible to classify response on the basis of multiple measurements rather than a
single one;
• It provides a direct estimate of the individual probability of pathological response rather than
simply discriminating between different histopathological responses.
To assess our results we address the properties of our model in terms of discrimination
(how well predicted probabilities separate patients with different responses) and prediction
accuracy (how well predicted probabilities agree with individual responses):
• Discrimination: We construct a Receiver Operating Characteristic (ROC) curve using the
predicted probability of response for each of the patients. This is useful to clarify the ability
to discriminate between responders and nonresponders.
• Prediction accuracy:
• To assess the ability to make in-sample predictions we plot predicted probabilities of histo-
pathological response against observed histopathological response and we report the
(McFadden) Pseudo R2, a measure of the improvement in prediction ability above a model
with only a constant term.
• To assess the ability to make out-of-sample predictions, we perform leave-one-out-cross-
validation (LOOCV), a commonly used validation method [27, 28]. This amounts to
repeating the logistic regression 33 times. Each time one patient is left out for validation
and the set of observations used to make a prediction is composed of the remaining 32
patients. This gives a better idea of the ability to predict pathological response on the basis
of TLG measurements, because the probability of pathological response of each patient is
computed without using their data.
All statistical analyses were performed using STATA/SE 11.2 software (Stata Corp. LP, Col-
lege Station, TX, USA).
Results
In the following we begin by giving a description of TLG measurements and their association
with histopathological response. We then present the models to predict major response and
complete response.
TLG measurements
The comparisons between TLG measurements at different times were performed using the
Wilcoxon signed-rank test. The average early reduction in TLG (reduction from baseline to
Response to Short Course RT in LARC with FDG-PET/CT
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early measurement) was 50% (P< 0, 0000). The average delayed reduction in TLG (reduction
from early to delayed measurement) was 50% (P< 0, 0000). The average overall reduction in
TLG (reduction from baseline to delayed measurement) was 83% (P< 0, 0000).
TLG measurements and histopathological responses
Absolute values of TLG parameter levels and their changes after treatment were correlated
with pathological response using the Kruskal-Wallis equality-of-populations rank test.
The TRG groups are statistically related to early and delayed measurement of TLG
(P = 0.0001 and P = 0.0005, respectively), but not to baseline values (P = 0.1110). The TRG
groups are also statistically related to early and overall reductions in TLG (P = 0.0119 and
P = 0.0110, respectively), but not to delayed reductions (P = 0.6170).
Major response is statistically related to early and overall reductions in TLG. Average early
reduction in TLG is 56% for responding tumors compared to 43% for nonresponding tumors
(P = 0.0089). Average overall reduction in TLG is 88% for responding tumors, compared to
77% for nonresponding tumors (P = 0.0042).
Major response is not statistically related to delayed reductions in TLG. Average delayed
reduction in TLG is 44% for responding tumors compared to 54% for nonresponding tumors
(P = 0.8005).
Predicting response
Our analysis indicates significant metabolic responses to SCRTDS (SUVmax, SUVmean, or
TLG) already at the early PET and a clear correlation between these measurements of meta-
bolic response and TRG. Nevertheless, in line with the findings in [20], reductions in individ-
ual SUV and TLG values are insufficient for a clinically useful classification of patients as
major responders (TRG1-2) or nonresponders (TRG3-4):
• Reductions from baseline to early measurement classify correctly no more than 25 of 33
patients (75.76% of the total);
• Reductions from baseline to delayed measurement classify correctly no more than 27 of 33
patients, (81.82% of the total).
In contrast to these discouraging results, we find that a simple logistic regression model
based on two measurements (the early measurement of TLG and the overall proportional
reduction in TLG from the early to the delayed measurement) has a remarkable ability to clas-
sify patients and predict their histopathological response.
Predicting major response
To predict major response we find that the best specification of a logistic model includes only
the level of TLG at the early PET and the overall proportional reduction of TLG from the base-
line to the delayed PET. We denote by TLGBaseline, TLGEarly and TLGDelayed the baseline,
early, and delayed measurements of TLG and by OverallReductionTLG the proportional overall
reduction in TLG between the baseline and the delayed measurement
OverallReductionTLG ¼
TLGBaseline   TLGDelayed
TLGBaseline
Our results for the probability of major response (TRG1-2) computed with a logistic regres-
sion with TLGEarly, OverallReductionTLG, and a constant term are summarized in Table 2.
Response to Short Course RT in LARC with FDG-PET/CT
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The early measurement of TLG and the proportional overall reduction in TLG measure-
ments have the expected signs (higher early measurement of TLG and smaller overall reduc-
tions in TLG measurements lead to a lower probability of pathological response) and are both
significant. The constant term is also significant. Pseudo R2 is 0.8414.
On the basis of these results the probability of major response can be computed in the fol-
lowing way. First, use the coefficients in Table 2 to compute X, a linear combination of
TLGEarly and OverallReductionTLG as in Eq (1)
X ¼   13:4911   :3198  ðTLGEarlyÞ þ 37:8934  ðOverallReductionTLGÞ: ð1Þ
Then, use X to compute the probability of response according to the following formula:
1
1þ e  X
:
We construct a ROC curve using the predicted probability of response for each of the 33
patients (Fig 3). This is useful to clarify the ability of the predicted probability of response to
discriminate between major responders (TRG1-2) and nonresponders (TRG3-4). The result is
shown in Fig 3. The area under the curve (AUC) is 0.9926 and its 95% confidence interval is
[0.9750, 1.00000]. Setting a cut point of 0.5806 leads to 32 of the 33 patients (96.97%) being
correctly classified (only one responding patient is incorrectly classified as nonresponding)
and to sensitivity of 93.33% and specificity of 100%.
To assess in-sample prediction accuracy, for each individual patient we plot in Fig 4 the pre-
dicted probability of response (black bar) and their observed histopathological response. For
26 of 33 patients the model predicts the histopathological response with near certainty. For 13
of the 15 major responders (TRG1-2) the model predicts a probability of being a responder no
lower than 0.9933 and for 13 of 18 nonresponders the model predicts a probability of being
responder no higher than 0.004. For the remaining two responding patients (both with TRG2)
the model predicts probabilities of being a major responder of 0.58 and 0.22 and for the
remaining 5 nonresponders the model predicts probabilities of being a responder between
0.05 and 0.56.
To assess the ability of our model to make out-of-sample predictions, we performed leave-
one-out-cross-validation (LOOCV). The results are reported in Fig 4 (gray bars). Cross valida-
tion leads to no notable changes when predictions are nearly certain (predicted probabilities
very near 0 or 1). But LOOCV leads to different predictions in the case of 4 of the 7 patients
for whom predictions were not nearly certain.
The previous analysis reveals that for most of the patients our model makes it possible to
make predictions that are virtually certain and that are robust in the sense that the prediction
is unchanged when the patient’s observation is dropped.
Predicting complete response
To predict complete response we find that the best specification of a logistic model includes
only the level of TLG at the early PET and the overall proportional reduction of TLG from the
Table 2. Prediction of major response: Results of logistic regression analysis.
Coefficient Robust Std. Err. z P > |z| 95% Conf. Interval
TLGEarly −.3198 .1215 −2.63 0.008 [−.55788, −.08162]
OverallReductionTLG 37.8934 14.3964 2.63 0.008 [9.6770, 66.1097]
Constant −13.4911 5.0289 −2.68 0.007 [−23.3476, −3.6345]
doi:10.1371/journal.pone.0169462.t002
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baseline to the delayed PET. Our results for the probability of complete response (TRG1) com-
puted with a logistic regression with TLGEarly, OverallReductionTLG and a constant term are
summarized in Table 3.
The early measurement of TLG and the overall reduction in TLG measurements have the
expected signs (higher early measurements of TLG and smaller overall reductions in TLG
measurements lead to a lower probability of a complete pathological response) and are both
significant. The constant term is also significant. Pseudo R2 is 0.6710.
On the basis of these results the probability of complete response can be computed in the
following way. First, use the coefficients in Table 3 to compute Y, a linear combination of
TLGEarly and OverallReductionTLG as in Eq (2)
Y ¼   21:5914   :0783  ðTLGEarlyÞ þ 24:9975  ðOverallReductionTLGÞ: ð2Þ
Then, use Y to compute the probability of response according to the following formula:
1
1þ e  Y
:
We construct a ROC curve using the predicted probability of complete response for each of
the 33 patients. This is useful to clarify the ability of the predicted probability of response to
Fig 3. ROC Analysis for prediction of major response (TRG1-2).
doi:10.1371/journal.pone.0169462.g003
Response to Short Course RT in LARC with FDG-PET/CT
PLOS ONE | DOI:10.1371/journal.pone.0169462 January 6, 2017 8 / 15
discriminate between complete responders (TRG1) and not complete responders (TRG2-4).
The result is shown in Fig 5.
The area under the curve (AUC) is 0.9550 and its 95% confidence interval is [0.8877, 1].
Using a cut point of .5580 gives a sensitivity of 100% a specificity of 92% and allows classifying
correctly 93.94% of the patients, i.e., all but two patients with TRG2 who are incorrectly classi-
fied as complete responders. Using a cut point of .8905 gives a sensitivity of 37.50% a specificity
of 100.00% and allows classifying correctly 84.85% of the patients (5 of the 8 complete
responders are incorrectly classified as not complete responders, all the remaining 28 patients
are correctly classified).
Results for in-sample (black bars) and out-of-sample (gray bars) prediction accuracy of
complete response for each individual patient are plotted in Fig 6.
The comparison of predicted probabilities with predicted probabilities with LOOCV reveals
that the predictions of our model are robust to the exclusion of the patient’s observation from
the training set.
Fig 4. Prediction of major response. In sample (black bars, TRG1-2) and out of sample (LOOCV, gray bars, TRG1-2).
doi:10.1371/journal.pone.0169462.g004
Table 3. Prediction of complete response: Results of logistic regression analysis.
Coefficient Robust Std. Err. z P > |z| 95% Conf. Interval
TLGEarly −.0783 .0311 −2.52 0.012 [−.1393, −.01741]
OverallReductionTLG 24.9975 10.2491 2.44 0.015 [4.9097, 45.0853]
Constant −21.5914 9.6301 −2.24 0.025 [−40.4660, −2.7168]
doi:10.1371/journal.pone.0169462.t003
Response to Short Course RT in LARC with FDG-PET/CT
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Discussion
Two previous studies [20, 21] have analyzed the responses to SCRT in LARC and have docu-
mented no significant metabolic responses to SCRT. One study [20] finds no correlation
between metabolic response and TRG. On the basis of these results, it is generally accepted
that in LARC measurements of metabolic response cannot be used to drive therapeutic strate-
gies after SCRT.
Our results indicate that this conclusion is unwarranted. To understand why, it is important
to indicate the reasons for which our analysis differs from the referred works.
The first reason is that, since we adopted a protocol with delayed surgery, we perform three
PET scans, rather than two, and measurements of both metabolic and pathological response to
SCRT are taken at later times. The first PET scan after SCRT (early PET) is performed on aver-
age 10.1 days after the end of SCRT, rather than the last day of radiotherapy or 2 days after; the
second PET scan after SCRT (delayed PET) is performed on average 53 days after the end of
SCRT; moreover, because surgery is performed on average 60.3 days after the end of SCRT,
rather than 1 week after, TRG measurements provide an indication of the cumulative effect of
SCRT after a longer period. This has three advantages. First, early PET measurements may be
a more precise measurement of metabolic response; second, we have available an additional
measure of metabolic response (delayed PET); third, TRG may provide a more reliable
Fig 5. ROC Analysis for prediction of complete response (TRG1).
doi:10.1371/journal.pone.0169462.g005
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measurement of response when the effects of killing and apoptosis of tumor cells had probably
had sufficient time to be fully detected on histopathological analysis [29, 30].
The second reason is that, rather than using the reduction in a single PET measurement, we
consider the possibility of aggregating several measurements of metabolic response to make
inferences about the likely pathological response.
The third reason is that, rather than simply asking what threshold gives the best classifica-
tion of pathological responses, we provide a direct estimate of the probability of response for
each individual patient.
Our analysis indicates significant metabolic responses to SCRT (SUVmax, SUVmean, or
TLG) already at the early PET, as well as a clear correlation between these measurements of
metabolic response and TRG. As previously mentioned, this may be due to the fact that we
rely on more precise measurements of metabolic and pathological response. Despite being sig-
nificant, the ability of these measurements to classify patients in terms of their TRG could not
be considered satisfactory. Reductions in SUVmean and TLG classify correctly no more than
25 of 33 patients (or 75.76% of the total) as being major responders (TRG1-2) or nonrespond-
ers (TRG3-4).
A possible reason why reductions from baseline to early measurements perform poorly in
classifying patients is that the metabolic response to SCRT may be slow. Our findings provide
a moderate support to this view, given that reductions from baseline to delayed measurements
in SUVmean and TLG allow a minor increase in the ability to classify patients correctly: reduc-
tions from baseline to delayed measurements in SUVmean and TLG make it possible to clas-
sify correctly 26 and 27 patients, respectively (or 78.79% and 81.82% of the total) as being
Fig 6. Prediction of complete response. In sample (black bars, TRG1) and out of sample (LOOCV, gray bars, TRG1).
doi:10.1371/journal.pone.0169462.g006
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major responders (TRG1-2) or nonresponders (TRG3-4). Even so, the ability to classify
patients’ pathological responses to SCRT seems equally insufficient to propose clinically useful
classification.
When we consider the possibility of aggregating different measures of metabolic behavior
at different times with a logistic regression model, we find that the best specification is based
on the level of TLG at the early PET and on the overall proportional reduction of TLG from
the baseline to the delayed PET. The fact that TLG measurements are the best predictors of
pathological response to SCRT is not entirely surprising. Previous statistical analyses of large
samples of rectal cancer treated with CHRT [31] established a relation between tumor dimen-
sion and pathological response. TLG, as the product of SUV and metabolic volume, probably
conveys information on both tumor dimension and metabolic behavior.
With our specification, based on TLG measurements, we obtain two results. The first is that
we can classify correctly 32/33 patients (96.97%) as major responders (TRG1-2) or nonre-
sponders (TRG3-4) and 31/33 patients (93.94%) as complete responders (TRG1) or not com-
plete responders (TRG2-4). The second, more important, is that we provide simple formulas
to compute the likelihood of an individual patient being a major responder or a complete
responder on the basis of their TLG measurements. These simple formulas make it possible to
estimate the probability of response prior to surgery. A more extensive patient panel would
probably strengthen the prediction power, but there is evidence that the proposed formulas
already provide references that should not be ignored for clinical purposes.
Conclusion
Our findings show that logistic regression can be used to aggregate multiple metabolic mea-
surements and achieve remarkable predictive ability of pathological response to SCRT. The
straightforward prediction formulas we propose make it possible to assess the risks associated
to LARC borne by a patient after SCRT. These risk assessments can be balanced against other
health risks associated with further treatments and can therefore be used to make informed
therapy adjustments after SCRT, for example, proceeding with complete surgery, practicing
local excision, or leaning for a wait and see policy. Future research applying the same method-
ology will be useful to validate and fine-tune our formulas and ultimately improve the ability
to predict pathological response.
Supporting Information
S1 File. Patient data.
(XLSX)
Author Contributions
Conceptualization: BP MC SL DR PD.
Data curation: BP CC MC SL FT AA DR MM AB LA PD GDP PM FB.
Formal analysis: BP CC MC.
Funding acquisition: AA AB AP.
Investigation: BP CC MC SL FT AA DR MM AB LA PD GDP PM FB.
Methodology: BP MC.
Project administration: BP CC PD.
Response to Short Course RT in LARC with FDG-PET/CT
PLOS ONE | DOI:10.1371/journal.pone.0169462 January 6, 2017 12 / 15
Resources: BP MC AA AP SL.
Software: BP CC MC SL FT AA DR MM AB LA PD GDP PM FB.
Supervision: BP CC MC SL AA DR MM AB LA PD.
Validation: BP MC MM.
Visualization: BP MC SL FT.
Writing – original draft: BP MC.
Writing – review & editing: BP MC SL.
References
1. Latkauskas T, Pauzas H, Gineikiene I, Janciauskiene R, Juozaityte E, Saladzinskas Z, et al. Initial
results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer
after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed sur-
gery. Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and
Ireland. 2012; 14(3):294–8. Epub 2011/09/09. doi: 10.1111/j.1463-1318.2011.02815.x PMID:
21899712.
2. Bujko K, Kolodziejczyk M. The 5 x 5 Gy with delayed surgery in non-resectable rectal cancer: a new
treatment option. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiol-
ogy and Oncology. 2008; 87(3):311–3. Epub 2008/01/22. doi: 10.1016/j.radonc.2007.12.020 PMID:
18207596.
3. Beppu N, Matsubara N, Noda M, Yamano T, Kakuno A, Doi H, et al. Short-course radiotherapy with
delayed surgery versus conventional chemoradiotherapy: A comparison of the short- and long-term out-
comes in patients with T3 rectal cancer. Surgery. 2015; 158(1):225–35. doi: 10.1016/j.surg.2015.03.
014 PMID: 25900036
4. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radio-
therapy with delayed surgery in primary rectal cancer. The British Journal of Surgery. 2012; 99(4):577–
83. Epub 2012/01/14. doi: 10.1002/bjs.7796 PMID: 22241246
5. Bujko K, Partycki M, Pietrzak L. Neoadjuvant radiotherapy (5 x 5 Gy): immediate versus delayed sur-
gery. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches
sur le cancer. 2014; 203:171–87. PMID: 25103005
6. Pettersson D, Lorinc E, Holm T, Iversen H, Cedermark B, Glimelius B, et al. Tumour regression in the
randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. The British Journal of Sur-
gery. 2015; 102(8):972–8; discussion 8. doi: 10.1002/bjs.9811 PMID: 26095256
7. Radu C, Berglund A, Pahlman L, Glimelius B. Short-course preoperative radiotherapy with delayed sur-
gery in rectal cancer—a retrospective study. Radiotherapy and Oncology: Journal of the European
Society for Therapeutic Radiology and Oncology. 2008; 87(3):343–9. doi: 10.1016/j.radonc.2007.11.
025 PMID: 18093674
8. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, et al. Short-course radiother-
apy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor per-
formance status or significant co-morbidity. Radiotherapy and Oncology: Journal of the European
Society for Therapeutic Radiology and Oncology. 2009; 92(2):210–4. doi: 10.1016/j.radonc.2009.04.
007 PMID: 19409638
9. Valentini V, Glimelius B, Haustermans K, Marijnen CA, Rodel C, Gambacorta MA, et al. EURECCA
consensus conference highlights about rectal cancer clinical management: the radiation oncologist’s
expert review. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology
and Oncology. 2014; 110(1):195–8. doi: 10.1016/j.radonc.2013.10.024 PMID: 24286634
10. Smith FM, Waldron D, Winter DC. Rectum-conserving surgery in the era of chemoradiotherapy. The
British Journal of Surgery. 2010; 97(12):1752–64. Epub 2010/09/17. doi: 10.1002/bjs.7251 PMID:
20845400
11. Rupinski M, Szczepkowski M, Malinowska M, Mroz A, Pietrzak L, Wyrwicz L, et al. Watch and wait pol-
icy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clini-
cally benign. European Journal of Surgical Oncology: the Journal of the European Society of Surgical
Oncology and the British Association of Surgical Oncology. 2016; 42(2):288–96. doi: 10.1016/j.ejso.
2015.09.022 PMID: 26506863
Response to Short Course RT in LARC with FDG-PET/CT
PLOS ONE | DOI:10.1371/journal.pone.0169462 January 6, 2017 13 / 15
12. Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer follow-
ing neoadjuvant chemoradiation therapy. The American Journal of Gastroenterology. 2004; 99(1):109–
12. Epub 2003/12/23. PMID: 14687151
13. Denecke T, Rau B, Hoffmann KT, Hildebrandt B, Ruf J, Gutberlet M, et al. Comparison of CT, MRI and
FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preop-
erative therapy: is there a benefit in using functional imaging? European Radiology. 2005; 15(8):1658–
66. Epub 2005/04/05. doi: 10.1007/s00330-005-2658-4 PMID: 15806369
14. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH. How accurate is magnetic resonance imaging in restag-
ing rectal cancer in patients receiving preoperative combined chemoradiotherapy? Diseases of the
colon and rectum. 2005; 48(4):722–8. Epub 2005/03/05. doi: 10.1007/s10350-004-0851-1 PMID:
15747073
15. Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P, et al. 18F-FDG PET is an early pre-
dictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal can-
cer. Journal of Nuclear Medicine: Official publication, Society of Nuclear Medicine. 2006; 47(8):1241–8.
Epub 2006/08/03. PMID: 16883000.
16. Avallone A, Aloj L, Caraco C, Delrio P, Pecori B, Tatangelo F, et al. Early FDG PET response assess-
ment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term
outcome. European Journal of Nuclear Medicine and Molecular Imaging. 2012; 39(12):1848–57. Epub
2012/10/12. doi: 10.1007/s00259-012-2229-2 PMID: 23053320
17. Janssen MH, Ollers MC, Riedl RG, van den Bogaard J, Buijsen J, van Stiphout RG, et al. Accurate pre-
diction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using
(18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat
Oncol Biol Phys. 2010; 77(2):392–9. Epub 2009/07/29. doi: 10.1016/j.ijrobp.2009.04.030 PMID:
19646825
18. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, et al. Utility of PET, CT, and EUS
to identify pathologic responders in esophageal cancer. The Annals of Thoracic Surgery. 2004; 78
(4):1152–60; discussion -60. Epub 2004/10/07. doi: 10.1016/j.athoracsur.2004.04.046 PMID:
15464463
19. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, et al. FDG-PET in the prediction of pathologic
response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
International Journal of Radiation Oncology, Biology, Physics. 2005; 63(4):1053–9. Epub 2005/06/21.
doi: 10.1016/j.ijrobp.2005.03.033 PMID: 15964705
20. Siegel R, Dresel S, Koswig S, Gebauer B, Hunerbein M, Schneider W, et al. Response to preoperative
short-course radiotherapy in locally advanced rectal cancer: value of f-fluorodeoxyglucose positron
emission tomography. Onkologie. 2008; 31(4):166–72. Epub 2008/04/18. doi: 10.1159/000118037
PMID: 18418017
21. Janssen MH, Ollers MC, van Stiphout RG, Buijsen J, van den Bogaard J, de Ruysscher D, et al. Evalua-
tion of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy
alone: sequential FDG-PET-CT findings. Radiotherapy and Oncology: Journal of the European Society
for Therapeutic Radiology and Oncology. 2010; 94(2):151–5. Epub 2010/02/02. doi: 10.1016/j.radonc.
2009.12.033 PMID: 20116114
22. Janssen MH, Aerts HJ, Buijsen J, Lambin P, Lammering G, Ollers MC. Repeated positron emission
tomography-computed tomography and perfusion-computed tomography imaging in rectal cancer:
fluorodeoxyglucose uptake corresponds with tumor perfusion. International Journal of Radiation Oncol-
ogy, Biology, Physics. 2012; 82(2):849–55. Epub 2011/03/12. doi: 10.1016/j.ijrobp.2010.10.029 PMID:
21392896
23. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O’Connell MJ, Begovic M, et al. Impact of T and N
stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. Journal of Clin-
ical Oncology: Official Journal of the American Society of Clinical Oncology. 2004; 22(10):1785–96.
Epub 2004/04/07. doi: 10.1200/JCO.2004.08.173 PMID: 15067027.
24. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting
photon beam therapy (Report 50). Bethesda, MD: International Commission on Radiation Units and
Measurements; 1993. viii, 72 p. p.
25. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting
photon beam therapy (Report 62). Bethesda, Md.: International Commission on Radiation Units and
Measurements; 1999. 52 p. p.
26. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assess-
ment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopath-
ologic Correlations. Cancer. 1994; 73(11):2680–6. Epub 1994/06/01. doi: 10.1002/1097-0142
(19940601)73:11%3C2680::AID-CNCR2820731105%3E3.0.CO;2-C PMID: 8194005
Response to Short Course RT in LARC with FDG-PET/CT
PLOS ONE | DOI:10.1371/journal.pone.0169462 January 6, 2017 14 / 15
27. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, et al. Integration of gene
expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prosta-
tectomy. Cancer. 2005; 104(2):290–8. Epub 2005/06/11. doi: 10.1002/cncr.21157 PMID: 15948174
28. Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O’Connor R, et al. A novel panel of protein bio-
markers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma
patients. Proteomics. 2011; 11(8):1391–402. Epub 2011/03/03. doi: 10.1002/pmic.201000471 PMID:
21365752
29. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval
between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-spar-
ing surgery for rectal cancer: the Lyon R90-01 randomized trial. Journal of Clinical Oncology: Official
Journal of the American Society of Clinical Oncology. 1999; 17(8):2396. Epub 1999/11/24. PMID:
10561302.
30. Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, Hermans J, van de Velde CJ, Leer JW, et al. No down-
staging after short-term preoperative radiotherapy in rectal cancer patients. Journal of Clinical Oncol-
ogy: Official Journal of the American Society of Clinical Oncology. 2001; 19(7):1976–84. Epub 2001/04/
03. PMID: 11283130.
31. van Stiphout RG, Lammering G, Buijsen J, Janssen MH, Gambacorta MA, Slagmolen P, et al. Develop-
ment and external validation of a predictive model for pathological complete response of rectal cancer
patients including sequential PET-CT imaging. Radiotherapy and Oncology: Journal of the European
Society for Therapeutic Radiology and Oncology. 2011; 98(1):126–33. Epub 2010/12/24. doi: 10.1016/
j.radonc.2010.12.002 PMID: 21176986
Response to Short Course RT in LARC with FDG-PET/CT
PLOS ONE | DOI:10.1371/journal.pone.0169462 January 6, 2017 15 / 15
